Welcome to the home of Canada's first clinically proven and regulatory approved treatment for Dry age-related macular degeneration.
- With MacuMira you can restore your vision and renew your life
- Our treatment is safe, pain-free, and administered by your local eye care professionals
- Improve your vision with short and easy treatments
- Book with your eye care professional or send them information on MacuMira today
Welcome to MacuMira
Our pain free, non-invasive treatments are helping people with dry Age-related macular degeneration (dry AMD), see again
- After the age of 45, 9% of the population will suffer from vision loss due to dry AMD.
- Over time your vision loss intensifies and your quality of life declines as you lose your independence and ability to to perform everyday tasks such as, driving, reading and recognizing faces.
- Current treatments aimed at slowing the progression of dry AMD include lifestyle changes, supplementation with nutraceuticals and regular eye injections.
- AMD is the leading cause of adult blindness.
- MacuMira is the first clinically proven treatment option providing a safe, easy and effective way to restore and improve your vision.
Overview
Age-related macular degeneration (AMD) Affects 2.5M Canadians
Dry AMD
- 85-90% of AMD
- Patients who suffer from this condition are advised to improve their lifestyle habits and take dietary supplements (nutraceuticals) that may slow down the progression of the disease
- Prescribed nutraceuticals provide 0% recovery of lost visual acuity
- Despite poor quality control and modest efficacy, over $2.5B of these eye health supplements are sold globally each year
Wet AMD
- 10-15% of AMD (more severe cases)
- Most people with wet AMD have progressed over time from dry AMD
- Treated by intraocular injections every 4-6 weeks for the duration of the patient’s life only to hopefully slow down the progression, not cure or improve vision
- Annual cost of injections in North America varies depending on plans and coverage, they are estimated at $1,200-$3,000 per treatment
Register here for more information
Interested in learning more about MacuMira? Register to stay informed on Technology Updates, New Clinical Trials, Technology Updates, Community Insights and Patient Testimonials
- Need Help?
Register for more information as a patient
"*" indicates required fields
Register for more information as a eye care-practitioner
"*" indicates required fields
How it Works
Our process is easy and practical. MacuMira can change your vision, which changes your life.
MacuMira focuses on client comfort and sustainability. Your vision therapy is administered by certified eye care professionals and the results are seen after the first treatments. The therapy requires a loading phase of 4 treatments within the first 10 days, then 1 treatment every 2-3 months
01.
Micro current
Painlessly delivered across closed eyelids with no injections, systemic drugs, or adverse side effects.
02.
Patented waveform
Developed to maximize efficacy while leaving the delicate structures of the eye undamaged.
03.
Patented delivery system
Simple to use and easily administered by a certified Eye Care Practitioner or Ophthalmic Technician.
04.
Immediate results
Optimal visual improvement reached after initial treatment schedule of four 32 minute treatments over 10 days.
05.
Visual improvements
Maintenance Phase: 1 treatment every 2-3 months
06.
Mechanism of Action
Stimulated Retinal Pigment Epithelium (RPE) cells enhanced Mitochondrial ATP formation leads to improved cellular function and clearing of drusen and other macular waste byproducts1.
Our clinically tested process will improve your vision, and can be maintained for the rest of your life with proper treatment.
Clinical Trial
60 patients enrolled in the trial with 40 in the treatment group and 20 in the placebo group
Treatment group:
- 48% of the patients improved by at least 10 letters on the ETDRS acuity chart
- All patients in the treatment group showed improved vision
- Improved by an average of 8.8 ETDRS letters along with a 25% average increase in ETDRS acuity with no adverse effects
- Treated patients maintained their visual improvements for the duration of the trial
Placebo group:
- Patient’s visual acuity down by 2% on average
Future Trials & Studies: Protocols and applications underway to study expanded Indications for Diabetic Retinopathy, DME, Wet AMD and Geographic Atrophy.
Testimonials
Revolutionary results with passionate patient reviews.
“I can see the street signs when I drive now, they are much clearer and brighter”
– Patient
“I can see the clock on the wall and tell time again, I can sew again which I have not done in years. This has
been life-changing”
– Patient
“I can get my drivers license again!!!”
– Patient